Immunoglobulin Market 2019 | Develop Rapidly by Players Baxter international Inc., CSL Ltd., Grifols S.A, Octapharma AG, Kedrion Biopharma Inc., LFB group, Biotest AG, China Biologics Products, Inc., BDI Pharma Inc

Increasing application of immunoglobulin is gaining significant traction among pharmaceutical and Biopharmaceuticals Company for the research and development of immunoglobulin. Moreover, increasing number of intravenous product approvals and clinical trials for new clinical applications is anticipated to provide potential growth opportunities to the industry.

Request a Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/1712

For instance, in May 2018, ADMA Biologics, Inc. announced that the company had received U.S. patent for treating respiratory infection. The patent consist of usage of polyclonal immunoglobulin preparation for treatment of respiratory infection, where the issued patent extends to January 2035.

Furthermore, Kedrioin Biopharma and Kamada Ltd. together in May 2018, launched two human-derived protein therapeutics companies announced that KEDRAB [Rabies Immune Globulin (Human)] has been launched in the U.S. as it has received U.S. Food and Drug Administration approval for passive, transient post-exposure prophylaxis of rabies infection, when given immediately after contact with a rabid or possibly rabid animal and concurrent with the rabies vaccine. Such advancement and launches in field of immunoglobulin are expected to foster growth of the immunoglobulin market in near future.

Increasing incidences of Primary Immunodeficiency Disease (PID) worldwide is also a major factor driving growth of the immunoglobulin market. As per Center for Disease Control and Prevention (CDC), in 2012, the incidence rate of hypogammaglobulinemia across the globe was around 2 per 100,000 populations annually and is expected to increase in near future.

Furthermore, increasing number of geriatric population, which is more prone to develop disease due to low antibody immune response of body is propelling the demand for immunoglobulin. However, high cost of treatment, long-term side-effects, stringent regulatory framework, and emergence of alternative therapies such recombinant products are expected to restrain growth of the immunoglobulin market.

The major players operating in the market include Baxter international Inc., CSL Ltd., Grifols S.A, Octapharma AG, Kedrion Biopharma Inc., LFB group, Biotest AG, China Biologics Products, Inc., BDI Pharma Inc., and Bayer Healthcare. Other players in the immunoglobulin market include Hualan Biological Engineering Inc., Omrix Biopharmaceuticals Ltd., Behring GmbH, Shanghai RAAS Blood Products Co., Ltd., Option Care Enterprises, Inc., ADMA Biologics, Inc., and BioScrip, Inc.

Get PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/1712

Immunoglobulin manufactures are involved in research and development to develop new immunoglobulin drug. For instance, GigaGen received US$ 3 million grant from the National Institutes of Health in January 2018, to develop novel antibody therapies to advance its next-generation plasma therapy for patients with immune deficiencies

Evolve Biologics, a division of Therapure Biopharma Inc. in May 2018, announced the start of phase III clinical trial of PlasmaCap IG (Intravenous Immunoglobulin or “IVIG”). The PlasmaCap IG is an investigational IVIG replacement therapy being studied in both adult and pediatric patients with Primary Immune Deficiency Diseases (PIDD). More such ongoing clinical trials are supporting growth of the immunoglobulin market.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Us:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.